about
Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not α-synuclein-induced neuronal cell lossImprovement with corticosteroids and azathioprine in GAD65-associated cerebellar ataxia.MRI reveals brain abnormalities in drug-naive Parkinson's disease.Free-water and BOLD imaging changes in Parkinson's disease patients chronically treated with a MAO-B inhibitor.Striatal and Hippocampal Atrophy in Idiopathic Parkinson's Disease Patients without Dementia: A Morphometric Analysis.Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease.An eight-year clinic experience with clozapine use in a Parkinson's disease clinic setting.The "brittle response" to Parkinson's disease medications: characterization and response to deep brain stimulation.Weight loss and impact on quality of life in Parkinson's disease.Unexpected dual task benefits on cycling in Parkinson disease and healthy adults: a neuro-behavioral model.Distinct patterns of brain activity in progressive supranuclear palsy and Parkinson's disease.Functional activity of the sensorimotor cortex and cerebellum relates to cervical dystonia symptoms.Deep brain stimulation response in pathologically confirmed cases of multiple system atrophyDistinct functional and macrostructural brain changes in Parkinson's disease and multiple system atrophy.Direct detection of alpha synuclein oligomers in vivoDriving errors in Parkinson's disease: moving closer to predicting on-road outcomes.A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease.Functional MRI of disease progression in Parkinson disease and atypical parkinsonian syndromesDefining the clinically meaningful difference in gait speed in persons with Parkinson disease.Viral expression of ALS-linked ubiquilin-2 mutants causes inclusion pathology and behavioral deficits in mice.The ER retention protein RER1 promotes alpha-synuclein degradation via the proteasome.Interferon-γ induces progressive nigrostriatal degeneration and basal ganglia calcification.Anti-tau antibodies: hitting the target.Depressive Symptoms are Frequent in Atypical Parkinsonian Disorders.Discriminating features of gait performance in progressive supranuclear palsy.Abnormal tactile pressure perception in Parkinson's diseasePostural/Gait and cognitive function as predictors of driving performance in Parkinson's diseaseGlobal attentional neglect of segmented lines in Parkinson's diseaseDissecting α-synuclein inclusion pathology diversity in multiple system atrophy: implications for the prion-like transmission hypothesis
P50
Q28538890-F05546D9-10D5-4DBB-A6B0-56573C04BC2AQ30441830-3CA8208E-FFF1-4EEA-9AEA-8CC50025B6FBQ30688718-EF5CDACA-CB21-4930-BD05-C9ADE2E16D60Q31080092-064C7875-A242-41CA-BCBC-4A39406C92EEQ33559200-8520643F-8217-411D-AA1F-8AA9A11E8F0FQ34301607-F505E853-5325-459B-BC6A-9B5BF6475738Q35124915-FE46C147-2734-4109-ABE4-83A397353040Q35147889-5757F6BE-F8E1-4657-A7B2-E5C33B07BA1BQ35566032-B16DC446-CEC8-49DD-AFC2-B2F9BA78786FQ35630608-E67754F2-ED79-483C-8CE0-84EF522B0E57Q36083388-B4F5AE59-51FF-4F2A-A15D-35D85C041AEEQ36395669-EEC38BCB-0311-432F-A626-3B56E650E359Q36670652-D5FEF6C0-6B2E-40B6-8AB6-14F952F23E81Q37108101-1EEE300E-FCDC-4E63-B4FF-A7AD2F5D0F98Q37180232-50F7C66A-F304-45CF-AD8A-1C0FC7E5B831Q37412123-851CA18A-D0E6-4070-BA99-16DA9A52F4F6Q38383918-72900C6B-3E71-41DE-8849-5F0191EF8600Q38841452-7B58C319-C7FB-41E1-B7E4-30F4B38DF360Q40220577-AE2D53C3-258E-41F5-8E0A-157C1944FC77Q40760984-5BDB956F-B20D-4124-B5BD-2A5B1620A12EQ41635176-E88ADC4B-D3DC-4AED-B1AB-091C6C1489AEQ41995272-1D89A148-7619-42E1-8722-112184B12D55Q45762971-27BF84E4-376D-4C57-97B5-937E83A5E7ECQ47759633-C9C12A1A-9EAD-4536-9BBA-006DDB8E4F80Q50970003-2BD8178C-C65F-49DD-91EC-D062AAA91A52Q86016533-BE642F0F-FF6E-4EB7-B881-5BF60332A90DQ87241825-0135EF42-5A12-4AA0-8CA5-8EA036591A50Q87467011-E2B20744-0173-4196-A81E-A4B473615639Q91429961-948D9636-8257-4E77-97A5-E84994D811D8
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Nikolaus R McFarland
@ast
Nikolaus R McFarland
@en
Nikolaus R McFarland
@es
Nikolaus R McFarland
@nl
type
label
Nikolaus R McFarland
@ast
Nikolaus R McFarland
@en
Nikolaus R McFarland
@es
Nikolaus R McFarland
@nl
altLabel
Nikolaus McFarland
@en
prefLabel
Nikolaus R McFarland
@ast
Nikolaus R McFarland
@en
Nikolaus R McFarland
@es
Nikolaus R McFarland
@nl
P1053
I-4209-2017
P106
P1153
6603403550
P31
P496
0000-0002-8699-8857